Eli Lilly Inks Deal Worth Up to $2.75B With AI Drug Firm Insilico
Pharma giant Eli Lilly teams up with Insilico Medicine on AI-powered drug co-development in a deal worth up to $2.75 billion.
Eli Lilly just made a massive bet on AI-driven pharmaceuticals. The U.S. pharma heavyweight signed a co-development agreement with Hong Kong-listed Insilico Medicine, an AI drug discovery company. The deal is worth up to $2.75 billion.
Insilico pockets $115 million in upfront payments, with the remaining value tied to the partnership's progression. The collaboration focuses on bringing AI-developed drugs through the pipeline — a signal that Big Pharma is increasingly willing to write enormous checks for machine learning-driven discovery.
Insilico Medicine has built its reputation on using artificial intelligence to accelerate the notoriously slow and expensive drug development process. For Lilly, this deal represents a significant commitment to AI as a core tool in its R&D strategy.
The numbers speak for themselves. Up to $2.75 billion is serious money, even for a company Lilly's size.